Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nrix · pe ratio · data through Nov 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Nurix Therapeutics, Inc. (NRIX) measures how much investors pay for each dollar of the company's trailing earnings. NRIX's current PE ratio of N/A is calculated by dividing its stock price of $16.04 by its TTM earnings per share of -$2.68.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-11-30
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Nurix Therapeutics, Inc.You NRIX | $1.4B | N/A | — | -$2.68 |
 BridgeBio Oncology Therapeutics Inc. BBOT | $627M | N/A | — | -$4.30 |
 EyePoint Pharmaceuticals, Inc. EYPT | $973M | N/A | — | -$3.17 |
 Fortrea Holdings Inc. FTRE | $1.6B | N/A | — | -$10.81 |
 Kodiak Sciences Inc. KOD | $1.6B | N/A | — | -$4.32 |
 Kura Oncology, Inc. KURA | $747M | N/A | — | -$3.18 |
 Phathom Pharmaceuticals, Inc. PHAT | $806M | N/A | — | -$3.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-11-30Latest FY2025 | — | $-3.05 | — | |
2024-11-30 FY2024 | — | $-2.88 | — | |
2023-11-30 FY2023 | — | $-2.65 | — | |
2022-11-30 FY2022 | — | $-3.71 | — | |
2021-11-30 FY2021 | — | $-2.73 | — | |
2020-11-30 FY2020 | — | $-2.76 | — | |
2019-11-30 FY2019 | — | $-0.56 | — | |
2018-11-30 FY2018 | — | $-0.59 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Nurix Therapeutics, Inc. (NRIX) measures how much investors pay for each dollar of the company's trailing earnings. NRIX's current PE ratio of N/A is calculated by dividing its stock price of $16.04 by its TTM earnings per share of -$2.68.
Frequently asked questions
NRIX pe ratio · 6 questionsNRIX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $16.04 and TTM EPS of -$2.68. Data sourced from Financial Modeling Prep via NRIX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nurix Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08